2011 National Guideline Clearinghouse | Antiemetics (nausea): American Society of Clinical Oncology clinical practice guideline update. Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, February 20, 2012

2011 National Guideline Clearinghouse | Antiemetics (nausea): American Society of Clinical Oncology clinical practice guideline update.




also note: 

FDA Warning/Regulatory Alert
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.
  • September 15, 2011 – Zofran (ondansetron) External Web Site Policy: The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients of an ongoing safety review and labeling changes for the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and generics). Ondansetron may increase the risk of developing prolongation of the QT interval of the electrocardiogram, which can lead to an abnormal and potentially fatal heart rhythm, including Torsade de Pointes.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.